Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ING2 | Q9H160 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8847257 | 0.76 | KDM4E (0.47) | KDM4ENAPRTLCKFYNTSHR | |
| SCHEMBL5549771 | 0.74 | KDM4E (0.39) | KDM4E | |
| SCHEMBL31696807 | 0.69 | ALDH1A1 (0.44) | KDM4ETSHRSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL3718026 | 0.69 | TRIM24 (0.50) | KDM4ENAPRTSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL28565819 | 0.68 | ALDH1A1 (0.42) | KDM4ETSHRSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL30023628 | 0.67 | ALDH1A1 (0.41) | KDM4ETSHRSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL29949354 | 0.67 | ALDH1A1 (0.55) | KDM4EALDH1A1LMNA | |
| SCHEMBL9768733 | 0.67 | ING2 (0.44) | KDM4EING2ALDH1A1 | |
| SCHEMBL867464 | 0.67 | ALDH1A1 (0.41) | KDM4ETSHRSMN1; SMN2TDP1ALDH1A1 | |
| SCHEMBL26777577 | 0.67 | ALDH1A1 (0.41) | KDM4ETSHRSMN1; SMN2TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2007-11-29 | — | — | US | disclosed |
| EP-1660011-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | Renovis, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | RENOVIS, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016272-A2 | ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS | RENOVIS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275932-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | KDM4E 3244/4885NAPRT 66/4885LCK 233/4885 |
| US-20050059638-A1 | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders | AHR, NAT1, ARNT | KDM4E 3244/4885NAPRT 66/4885LCK 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.